These words sum up the efforts of the Themis Group, which integrates people, processes and potential towards the betterment of mankind.

The company was promoted by Mr. Shantibhai D. Patel, a pioneer in Indian Pharmaceuticals Business. Themis Medicare is a joint venture pharmaceutical company, with Gedeon Richter Ltd., Hungary. The company in over three decades has made its presence felt in manufacturing and marketing innovative pharmaceutical products.

Themis Medicare is headquartered in Mumbai with four state-of-the-art manufacturing facilities at three locations, in Vapi (Gujarat), Hyderabad (Andhra Pradesh), and Haridwar (Uttaranchal).

Even though, Active Pharmaceutical Ingredients account for a significant portion of Themis Medicare's revenue, the Company is setting new benchmarks in manufacturing and marketing formulations. The company has prudently addressed relevant and growing therapeutic areas like antituberculosis, antimalarials, cardiology, pain management, anti-infectives, haematinics, Health & Nutrition. The company is also engaged in co-marketing its research based formulations with other pharmaceutical companies in India and abroad.

The 500 strong field force of Themis Medicare, backed by a nation wide network of over 2000 stockists, ensures that the company's products are readily available across the nation. This combined with the quality of the products means that Themis Medicare is able to strengthen the hands of doctors by offering superior treatment and healthcare solutions. It is our constant endeavour to improve the quality of life by enabling people to do more, feel better and live longer.

Themis Medicare has an expanding international portfolio of affiliates across the globe with a presence in 40 countries. Additionally, company is planning to enter all 29 EU countries, USA, Canada, Australia with its unique research formulations. A balanced geographical presence coupled with a strong product flow form a wide therapeutic range serve as the business building blocks of the company.

Themis Medicare has ambitious plans for the years ahead. The emphasis is on post 2006 opportunities with greater focus on the International Markets, in particular Europe, Americas and Australasia.